Tivozanibenivolumab vs tivozanib monotherapy in patients with renal cell carcinoma (RCC) following 1 or 2 prior therapies including an immune checkpoint inhibitor (ICI): Results of the phase III TiNivo-2 study Meeting Abstract
| Authors: | Choueiri, T. K.; Motzer, R. J.; Beckermann, K.; Barthelemy, P.; Iacovelli, R.; Emambux, S.; Molina Cerrillo, J.; Garmezy, B.; Coelho Barata, P. M.; McKay, R. R.; Chehrazi-Raffle, A.; Hammers, H.; Heng, D. Y. C.; Braendle, E.; McGregor, B. A.; Albiges, L. |
| Abstract Title: | Tivozanibenivolumab vs tivozanib monotherapy in patients with renal cell carcinoma (RCC) following 1 or 2 prior therapies including an immune checkpoint inhibitor (ICI): Results of the phase III TiNivo-2 study |
| Meeting Title: | ESMO Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sept 13-17 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | 1261 |
| End Page: | 1262 |
| Language: | English |
| ACCESSION: | WOS:001326612903083 |
| DOI: | 10.1016/j.annonc.2024.08.2316 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA73 -- Source: Wos |
